Daniel Stupak, MD
Gastroenterology · Trumbull, CTNPI 1669664314
Payments from drug & device makers
Across 622 payments — averaging $75.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- Phathom Pharmaceuticals, Inc.$10K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$7K
- Ironwood Pharmaceuticals, Inc$5K
- Nestle Healthcare Nutrition Inc.$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- plus $7K from 25 others
What the payments were for
- Speaking & faculty fees$33,34071%
- Travel & lodging$1220%
- Food & beverage$13,35629%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 122 | $13,415 |
| Phathom Pharmaceuticals, Inc. | 24 | $9,598 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 49 | $7,159 |
| Ironwood Pharmaceuticals, Inc | 24 | $5,224 |
| Nestle Healthcare Nutrition Inc. | 7 | $3,054 |
| Takeda Pharmaceuticals U.S.A., Inc. | 77 | $1,544 |
| Johnson & Johnson(2 entities) | 41 | $931 |
| Ardelyx, Inc. | 48 | $870 |
| Ipsen Biopharmaceuticals, Inc | 20 | $685 |
| Pfizer | 29 | $619 |
| Aimmune Therapeutics, Inc. | 13 | $550 |
| QOL Medical, LLC | 25 | $513 |
| Bristol Myers Squibb | 30 | $455 |
| Sanofi | 13 | $380 |
| Gilead | 18 | $325 |
| Lilly USA, LLC | 18 | $295 |
| Intercept Pharmaceuticals, Inc. | 9 | $193 |
| Madrigal Pharmaceuticals | 14 | $185 |
| Vivus LLC | 7 | $140 |
| Redhill Biopharma Inc. | 7 | $138 |
| E.r. Squibb & Sons, L.L.C. | 2 | $130 |
| Ferring Pharmaceuticals Inc. | 6 | $128 |
| Merck | 6 | $109 |
| Regeneron Healthcare Solutions, Inc. | 4 | $80 |
| Braintree Laboratories, Inc. | 2 | $40 |
| Mirum Pharmaceuticals, Inc. | 1 | $22 |
| Amgen | 1 | $21 |
| Intra-sana Laboratories | 1 | $20 |
| Novo Nordisk | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Gastrogpo, LLC | 2 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,863 in reported general payments places this provider in the 85th percentile of 326 gastroenterology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 145 | $160,578 |
| XifaxanRifaximin | 14 | $45,176 |
| IbsrelaTenapanor Hcl | 11 | $28,278 |
| CreonLipase/Protease/Amylase | 12 | $16,970 |
| TrulancePlecanatide | 20 | $15,849 |
| MovantikNaloxegol Oxalate | 23 | $14,479 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 39 | $6,859 |
| Omeprazole | 314 | $4,709 |
| Dexlansoprazole DrDexlansoprazole | 18 | $4,118 |
| Sucralfate | 39 | $3,562 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 52 | $2,805 |
| Famotidine | 60 | $2,187 |
| Dicyclomine Hcl | 64 | $1,728 |
| Ondansetron OdtOndansetron | 29 | $972 |
| Pantoprazole Sodium | 117 | $875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $13,415 | $177,548157 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $7,159 | $61,02434 claims |
| Ardelyx, Inc.Ibsrela | $870 | $28,27811 claims |
| Redhill Biopharma Inc.Movantik | $138 | $14,47923 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $128 | $6,85939 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 326 gastroenterology providers in Connecticut.
Other gastroenterology in Trumbull
- Pramod MistryNew Haven$6M
- Salam ZakkoBristol$2.7M
- Paul FeuerstadtHamden$1.4M
- Angelo ParedesMiddletown$1.3M
- James FrestonFarmington$778K
- Jill GaidosNew Haven$750K
- Houman RezaizadehFarmington$720K
- James BoyerNew Haven$648K
- Guadalupe Garcia TsaoNew Haven$555K
- Loren LaineWest Haven$485K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.